24
2022-11
Suzhou, November 24, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results for its phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne in China, which demonstrated the good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects. Developed by Kintor Pharma’s proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the first topical PROTAC compound globally which has completed phase I clinical trial.
10
2022-11
Suzhou, November 10, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been selected for oral presentation at the annual meeting of the American Society of Hematology 2022 (ASH 2022), and the abstract is available on ASH’s official website.
27
2022-10
Suzhou, October 27, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne on 25 October 2022.
16
2022-10
Suzhou, October 16, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 ("pyrilutamide") in China for the treatment of acne vulgaris on 14 October 2022.
12
2022-10
Kintor Pharma: Q3 2022 Business Update at a Glance
Kintor Pharma: Q3 2022 Business Update at a Glance
29
2022-09
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC
Suzhou, September 29, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide (used to be called proxalutamide, GT0918) for the treatment of patients with androgen receptor positive (AR+) metastatic breast cancer (AR+ mBC) in China have been published in the international journal, European Journal of Cancer (2021 Impact Factor: 10.002, EJC) on September 28, 2022, further demonstrating the efficacy and safety of pruxelutamide in patients with AR+ mBC.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn